BTLA and neoplasm: While the HVEM/LIGHT pathway enhances the eradication of tumors, the binding of HVEM to BTLA, which is predominantly expressed in tumor-specific T-cells, suppresses the response of CD8+ T-cells and thus promotes immune evasion.